Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Other financing activities (2016 - 2017)

Rein Therapeutics (RNTX) has disclosed Other financing activities for 2 consecutive years, with $255000.0 as the latest value for Q4 2017.

  • On a quarterly basis, Other financing activities rose 54.55% to $255000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $165000.0, a N/A change, with the full-year FY2017 number at $2.3 million, up 1180.0% from a year prior.
  • Other financing activities was $255000.0 for Q4 2017 at Rein Therapeutics, down from $1.6 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.6 million in Q3 2017 to a low of -$1.9 million in Q2 2017.